Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?
Executive Summary
Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.
You may also be interested in...
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.
Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs
Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.
Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says
Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call